Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next

• Immunovant recently reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, where the drug did not achieve statistical significance on the primary CLASI-A endpoint at Week 12, leading the company to halt development for this indication.

• Despite observing numerical trends favoring IMVT-1402 and better responses in patients with deeper IgG reductions, Immunovant concluded that the combination of these data and a competitive treatment landscape did not justify further CLE development.

• We'll now examine how Immunovant's decision to stop IMVT-1402 development in cutaneous lupus reshapes its broader autoimmune investment narrative.

Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Immunovant Investment Narrative Recap

To own Immunovant today, you need to believe IMVT-1402 can still become a meaningful FcRn franchise across larger autoimmune indications, despite the company remaining loss making with no current revenue. The CLE setback does not appear to alter the near term focus on difficult to treat rheumatoid arthritis and Graves' disease, but it does highlight that effect size and indication choice remain the most important short term catalyst and the biggest risk to the story.

The CLE outcome fits into a pattern that was already emerging after the 2026 batoclimab TED Phase 3 miss, where Immunovant reaffirmed IMVT-1402 and Graves' disease as its core priorities. That earlier update, which emphasized 2027 Graves' readouts as potentially registrational, still looks like the most relevant milestone against which the CLE discontinuation will now be judged, particularly as investors weigh how concentrated the pipeline has become around a smaller set of indications.

Yet this renewed focus on fewer indications also increases investor exposure to one risk you should be aware of...

Read the full narrative on Immunovant (it's free!)

Immunovant's narrative projects $559.3 million revenue and $101.9 million earnings by 2029. This requires revenue growth from no revenue today and an earnings increase of about $640 million from -$538.2 million today.

Uncover how Immunovant's forecasts yield a $48.07 fair value , a 44% upside to its current price.

Exploring Other Perspectives

Before this CLE news, the most pessimistic analysts were only modeling about US$1.4 million of revenue by 2029 and tiny earnings, which is far below consensus and could become even more relevant if the halted CLE program reinforces concerns that IMVT-1402 may face tighter payer or trial hurdles in larger autoimmune settings.